Literature DB >> 31671434

Myeloid Sarcoma With CBFB-MYH11 Fusion (inv(16) or t(16;16)) Prevails in the Abdomen.

Joanna C Dalland1, Reid Meyer2, Rhett P Ketterling1,2, Kaaren K Reichard1.   

Abstract

OBJECTIVES: Myeloid sarcoma with CBFB-MYH11 fusion may be enriched in abdominal sites. The clinicopathologic features of 11 cases are reported.
METHODS: We collected clinical features, morphology, immunophenotype, and bone marrow (BM) involvement of myeloid sarcoma cases with CBFB-MYH11 fusion.
RESULTS: Eleven of 29 total myeloid sarcoma cases were CBFB-MYH11 positive and all 11 involved abdominal sites. The blastic infiltrate was associated with eosinophils in four of 11 cases and plasmacytoid dendritic cell (pDC) nodules in four of six cases. CD34, CD117, and myeloperoxidase were expressed in eight of nine, 10 of 10, and 10 of 10 cases, respectively. Ten of 10 cases showed no BM involvement.
CONCLUSIONS: Our current series, combined with a literature review, identifies a compelling series of 31 (94%) of 33 cases of myeloid sarcoma with CBFB-MYH11 fusion showing a marked predilection for abdominal sites. In addition, the lack of obvious associated eosinophils, presence of pDC nodules, and lack of concurrent BM involvement suggest that "myeloid sarcoma with CBFB-MYH11 fusion" may represent a unique phenomenon. © American Society for Clinical Pathology, 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Acute myeloid leukemia; Chloroma; Core binding factor; M4; M4eo; Myeloid sarcoma

Mesh:

Substances:

Year:  2020        PMID: 31671434     DOI: 10.1093/ajcp/aqz168

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  5 in total

1.  Impact of upfront chemotherapy on overall survival in isolated myeloid sarcoma.

Authors:  Konstantinos Lontos; Jonathan G Yabes; Rafic J Farah; Michael Boyiadzis
Journal:  Leukemia       Date:  2020-08-19       Impact factor: 11.528

2.  Clinical and molecular characterization of myeloid sarcoma without medullary leukemia.

Authors:  Hussein A Abbas; Patrick K Reville; Alexis Geppner; Caitlin R Rausch; Naveen Pemmaraju; Maro Ohanian; Koji Sasaki; Gautam Borthakur; Naval Daver; Courtney DiNardo; Carlos Bueso-Ramos; Sherry Pierce; Elias Jabbour; Guillermo Garcia-Manero; Marina Konopleva; Farhad Ravandi; Hagop Kantarjian; Tapan M Kadia
Journal:  Leuk Lymphoma       Date:  2021-08-12

3.  Clinical characteristics, treatment, and prognosis of 118 cases of myeloid sarcoma.

Authors:  Haiqiu Zhao; Zhenkun Dong; Dingming Wan; Weijie Cao; Haizhou Xing; Zhenzhen Liu; Jixin Fan; Haiqiong Wang; Runqing Lu; Yinyin Zhang; Qianqian Cheng; Zhongxing Jiang; Fei He; Xinsheng Xie; Rong Guo
Journal:  Sci Rep       Date:  2022-04-26       Impact factor: 4.996

4.  Acute hepatitis-like presentation with cholestasis of CBFB-MYH11-positive acute myeloid leukemia in an adult male: a case report.

Authors:  Irene Spinelli; Adriano De Santis; Laura Cesini; Mara Riminucci; Alessandro Corsi; Mariana Forlino; Elio Pietro Perrone; Clara Minotti; Claudio Cartoni
Journal:  J Med Case Rep       Date:  2022-07-31

Review 5.  Genetics and Epigenetics in Neoplasms with Plasmacytoid Dendritic Cells.

Authors:  Florian Renosi; Mary Callanan; Christine Lefebvre
Journal:  Cancers (Basel)       Date:  2022-08-26       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.